Related Experiment Video
Updated: Jul 26, 2025
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Contribution of MicroRNAs in the Development of Irritable Bowel Syndrome Symptoms
Pablo Thomas Dupont1, Irma Yadira Izaguirre-Hernández2, José María Remes-Troche3
1Instituto de Investigaciones Médico Biológicas, Universidad Veracruzana, Veracruz, Mexico. . pthomas@uv.mx.
Abstract:
Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder defined by disturbances in bowel habits and abdominal pain, in the absence of known organic pathology that affects between 5 to 10% of healthy populations. Despite improvements in detection and treatment, the pathogenesis of IBS has not been clarified. Several microRNAs (miRNAs) are involved in the pathogenesis of IBS through increased intestinal permeability, inflammation, and modulation of visceral hyperalgesia, and they may have the potential to be used as biomarkers and therapeutic targets. Here, we have summarized the recent advances about the role of miRNAs in the development of IBS symptoms and the possibility to use them as therapeutic targets to mitigate symptoms in IBS.
Insights
MicroRNAs (miRNAs) play a key role in the development of irritable bowel syndrome (IBS) by affecting gut permeability and inflammation. These miRNAs show potential as biomarkers and therapeutic targets for managing IBS symptoms.
Area of Science:
- Gastroenterology and Molecular Biology
- Focus on functional gastrointestinal disorders and molecular mechanisms
Background:
- Irritable bowel syndrome (IBS) is a prevalent chronic functional gastrointestinal disorder affecting 5-10% of the population.
- Characterized by altered bowel habits and abdominal pain without identifiable organic pathology.
- The precise pathogenesis of IBS remains unclear despite diagnostic and therapeutic advancements.
Purpose of the Study:
- To review recent findings on the involvement of microRNAs (miRNAs) in IBS pathogenesis.
- To explore the potential of miRNAs as diagnostic biomarkers for IBS.
- To evaluate miRNAs as therapeutic targets for mitigating IBS symptoms.
Main Methods:
- Literature review and synthesis of current research on miRNAs and IBS.
- Analysis of studies investigating miRNA roles in intestinal permeability, inflammation, and visceral hyperalgesia.
- Examination of the translational potential of miRNAs in IBS management.
Main Results:
- Multiple miRNAs are implicated in IBS development through mechanisms like increased intestinal permeability.
- miRNAs are involved in modulating inflammatory responses within the gut.
- Specific miRNAs contribute to the visceral hyperalgesia characteristic of IBS.
Conclusions:
- MicroRNAs are significantly involved in the pathophysiology of irritable bowel syndrome.
- miRNAs represent promising candidates for developing novel biomarkers for IBS diagnosis.
- Targeting specific miRNAs offers a potential therapeutic strategy for alleviating IBS symptoms.
More Related Videos
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...